Need milk? Domperidone for increasing breast milk supply

Clinical Question: What is the efficacy and safety of domperidone to increase milk supply in breastfeeding mothers?

Bottom Line: In mothers of pre-term infants, domperidone increases milk volume by ~90 ml more than placebo after 14 days, with an additional 1 in 5 women experiencing a 50% increase in milk supply. Doses above 30 mg/day are likely not needed and may increase the risk of arrhythmias. Optimal length of treatment unknown.

Evidence:

- Efficacy:
  - Newest systematic review of 5 placebo-controlled trials of 192 breastfeeding mothers of pre-term infants. All used 10mg PO TID for 5-14 days:
    - Mean increase in expressed breast milk volume: 88 ml/day over placebo.
    - Maternal adverse effects: no difference.
    - Infant adverse effects: either no difference or not reported.
  - Largest RCT from above systematic review (90 mother-baby pairs):
    - Women with 50% increase in milk supply at 14 days: 78% domperidone versus 58%, Number Needed to Treat (NNT)=5.
    - Mean daily milk volume: 267 ml domperidone versus 168 ml (not statistically different, but likely underpowered).
    - No difference in breastfeeding rates at 6 weeks.

- Cardiac harms:
  - Canadian observational study of 45,518 women given domperidone in the 6 months postpartum:
    - Risk of hospitalizations for ventricular arrhythmia: 1.3/10,000 (domperidone) versus 0.55/10,000 (no domperidone): no statistical difference.
      - If real, would equal a number needed to harm of 12,950.
  - Systematic review of 6 case control studies, mainly in men over age 60:
    - Arrhythmia risk highest in doses >30 mg/day (OR=3.32) versus ≤30 mg/day (OR=1.63).
Context:
- Small RCTs (7-15 women) found no difference in efficacy between 30mg/day and 60mg/day.\textsuperscript{5,6}
- Low amounts of domperidone enter breastmilk (example <7mcg/day based on 80mg daily dose),\textsuperscript{7} but infant adverse effects similar to placebo.\textsuperscript{2,7}
- In 2015, Health Canada warned of domperidone use and abnormal heart rhythms/sudden cardiac death. While available evidence may not apply to breastfeeding population, domperidone is contraindicated if risk of arrhythmias (examples cardiac disease/conduction abnormalities, concurrent QTc prolonging drugs or potent CYP3A4 inhibitors).\textsuperscript{8}
- There is insufficient evidence on the use of herbal galactagogues (example fenugreek).\textsuperscript{9}

Authors:
Adrienne J Lindblad BSP ACPR PharmD & Tina Korownyk MD CCFP

Disclosure:
The authors have nothing to disclose.

References:

Tools for Practice is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD, CCFP and the content is written by practicing family physicians who are joined occasionally by a health professional from another medical specialty or health discipline. Each article is peer-reviewed, ensuring it maintains a high standard of quality, accuracy, and academic integrity. If you are not a member of the ACFP and would like to receive the TFP emails, please sign up for the distribution list at \url{http://bit.ly/signupfortfps}. Archived articles are available on the ACFP website.

This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.